Last reviewed · How we verify

Naloxone HCl PR tablets — Competitive Intelligence Brief

Naloxone HCl PR tablets (Naloxone HCl PR tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist. Area: Addiction Medicine / Emergency Medicine.

phase 3 Opioid antagonist Opioid receptors (mu, delta, kappa) Addiction Medicine / Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Naloxone HCl PR tablets (Naloxone HCl PR tablets) — Develco Pharma Schweiz AG. Naloxone HCl is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors without activating them.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Naloxone HCl PR tablets TARGET Naloxone HCl PR tablets Develco Pharma Schweiz AG phase 3 Opioid antagonist Opioid receptors (mu, delta, kappa)
Symproic NALDEMEDINE Bdsi marketed Opioid Antagonist Mu-type opioid receptor 2017-01-01
Movantik NALOXEGOL Averitas marketed Opioid Antagonist Mu-type opioid receptor 2014-01-01
Relistor METHYLNALTREXONE Salix Pharms marketed Opioid Antagonist Mu-type opioid receptor 2008-01-01
Entereg ALVIMOPAN Cubist Pharms marketed Opioid Antagonist µ-opioid receptor 2008-01-01
Revex NALMEFENE Hikma marketed Opioid Antagonist Kappa-type opioid receptor 1995-01-01
Narcan NALOXONE Adapt marketed Opioid Antagonist Mu-type opioid receptor 1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist class)

  1. Norwegian University of Science and Technology · 2 drugs in this class
  2. Green Cross Corporation · 1 drug in this class
  3. Middle Tennessee Research Institute · 1 drug in this class
  4. Develco Pharma Schweiz AG · 1 drug in this class
  5. Pacific Institute for Research and Evaluation · 1 drug in this class
  6. Pfizer · 1 drug in this class
  7. NYU Langone Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naloxone HCl PR tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/naloxone-hcl-pr-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: